Wednesday, Alnylam Pharmaceuticals, Inc. (ALNY) said its therapeutic ALN-VSP to treat patients with liver cancers, including hepatocellular carcinoma and other solid tumors, showed positive data in pre-clinical studies.
The pre-clinical trial data demonstrated robust anti-tumor activity in orthotopic liver tumor - of both HCC and colorectal cancer-derived cell lines. Studies showed ALN-VSP active on disseminated tumors outside of the liver, with a potent anti-angiogenic effect on tumors.
ALN-VSP is an RNAi therapeutic designed to target two genes critical in the growth and survival of cancer cells - kinesin spindle protein required for tumor cell proliferation; and vascular endothelial growth factor, required for blood vessel formation to sustain tumor growth.
The therapeutic ALN-VSP is currently in a phase I clinical trial for treatment of liver cancers and preliminary results of the trial are expected to be announced mid-2010. The phase I trial is a multicenter, open-label, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALN-VSP in patients with advanced solid tumors with liver involvement, including HCC.
ALN-VSP is formulated in collaboration with Tekmira Pharmaceuticals Corporation (TKM.TO).
ALNY is currently trading at $17.49, up $0.05, on the Nasdaq, while TKM.TO is trading at C$0.96, down C$0.02, on the Toronto Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.